KR20140054288A - Nedd8-활성화 효소의 억제제 - Google Patents

Nedd8-활성화 효소의 억제제 Download PDF

Info

Publication number
KR20140054288A
KR20140054288A KR1020147007200A KR20147007200A KR20140054288A KR 20140054288 A KR20140054288 A KR 20140054288A KR 1020147007200 A KR1020147007200 A KR 1020147007200A KR 20147007200 A KR20147007200 A KR 20147007200A KR 20140054288 A KR20140054288 A KR 20140054288A
Authority
KR
South Korea
Prior art keywords
chemical
added
chloro
methoxy
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020147007200A
Other languages
English (en)
Korean (ko)
Inventor
애슐리 슈 맥캐론
토드 비. 셀스
매튜 스털링
스테판 쥐. 스트로우드
Original Assignee
밀레니엄 파머슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밀레니엄 파머슈티컬스 인코퍼레이티드 filed Critical 밀레니엄 파머슈티컬스 인코퍼레이티드
Publication of KR20140054288A publication Critical patent/KR20140054288A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147007200A 2011-08-24 2012-08-23 Nedd8-활성화 효소의 억제제 Abandoned KR20140054288A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
US61/526,830 2011-08-24
PCT/US2012/052007 WO2013028832A2 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Publications (1)

Publication Number Publication Date
KR20140054288A true KR20140054288A (ko) 2014-05-08

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147007200A Abandoned KR20140054288A (ko) 2011-08-24 2012-08-23 Nedd8-활성화 효소의 억제제

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP2748168A4 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG11201400102WA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2015002994A2 (en) * 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
EP1597255A1 (en) 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
PL2773360T3 (pl) * 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Also Published As

Publication number Publication date
US20180290983A1 (en) 2018-10-11
US20130150388A1 (en) 2013-06-13
US9850214B2 (en) 2017-12-26
EP3323414A1 (en) 2018-05-23
CN103889988A (zh) 2014-06-25
EP2748168A4 (en) 2015-04-22
AU2012298813A1 (en) 2013-05-02
TN2014000080A1 (en) 2015-07-01
WO2013028832A2 (en) 2013-02-28
AR087672A1 (es) 2014-04-09
JP6038150B2 (ja) 2016-12-07
GEP201606522B (en) 2016-08-10
CA2846231A1 (en) 2013-02-28
AU2012298813B2 (en) 2016-07-28
EA201400249A1 (ru) 2014-05-30
PH12014500419A1 (en) 2020-06-22
TWI577667B (zh) 2017-04-11
CR20140128A (es) 2014-05-15
BR112014004239A2 (pt) 2017-03-21
MX2014002015A (es) 2014-03-27
CN103889988B (zh) 2018-05-04
PE20141146A1 (es) 2014-09-21
SG11201400102WA (en) 2014-03-28
US20150011572A1 (en) 2015-01-08
CO6900148A2 (es) 2014-03-20
US8809356B2 (en) 2014-08-19
MY166889A (en) 2018-07-24
HK1199252A1 (en) 2015-06-26
CA2846231C (en) 2017-06-20
UA114894C2 (uk) 2017-08-28
IL231069B (en) 2018-02-28
IL231069A0 (en) 2014-03-31
ECSP14013263A (es) 2014-04-30
UY34292A (es) 2013-04-05
JP2014524476A (ja) 2014-09-22
MA35439B1 (fr) 2014-09-01
EA031067B1 (ru) 2018-11-30
CL2014000441A1 (es) 2014-09-26
SG10201601023UA (en) 2016-03-30
NZ622220A (en) 2016-04-29
TW201313689A (zh) 2013-04-01
DOP2014000037A (es) 2014-04-15
EP2748168A2 (en) 2014-07-02
WO2013028832A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AU2012298813B2 (en) Inhibitors of Nedd8-activating enzyme
JP6184423B2 (ja) カルボン酸化合物
AU2024360867A1 (en) Substituted tricyclic compounds as kras degraders
EP3173413B1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN110698461A (zh) 第三代egfr抑制剂的制备方法
TWI613182B (zh) 雙環化合物
TWI904095B (zh) 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
CN117642396A (zh) αVβ6和αVβ1整联蛋白抑制剂及其用途
CA2956788A1 (en) Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease
AU2019206118B2 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
EP4582419A1 (en) Method for producing quinoxaline derivative
WO2022191092A1 (ja) キノリン化合物、hnmt阻害剤、及びadhd、ナルコレプシー又はアルツハイマーの予防・治療剤
CN121712748A (zh) 作为sstr4激动剂的(2s,5r)-5-(羟甲基)吗啉-2-甲酰胺
HK40087373A (zh) 氨基嘧啶基衍生物
NZ622220B2 (en) Inhibitors of nedd8-activating enzyme
KR20130018548A (ko) 5-(2,4-다이하이드록시-5-아이소프로필페닐)-엔-에틸-4-(5-메틸-1,2,4-옥사다이아졸-3-일)아이속사졸-3-카복사마이드 화합물의 전구약물
HK1187611B (en) Kat ii inhibitors
HK1187611A1 (en) Kat ii inhibitors
WO2015016729A1 (en) Urea compounds and their use as faah enzyme inhibitors
HK1126477A1 (en) Polymorphs of a c-met/hgfr inhibitor
HK1126477B (en) Polymorphs of a c-met/hgfr inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170821

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190318

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee